ReviewEndocrine2004
Hormones and bone health in postmenopausal women.
Review in Endocrine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Menopausal Hormone Treatment as a Preventive against the Progress of Chronic Diseases in Menopausal Women.Journal of menopausal medicine · 2026Review
- The U-curve associations of birth interval with prevalence of osteoarthritis in postmenopausal women.Aging clinical and experimental research · 2025Article
- Mandibular trabecular bone pattern before and two years after medical or surgical obesity treatment in young Swedish women.Clinical oral investigations · 2025Article
- Targeting the FSH/FSHR axis in ovarian cancer: advanced treatment using nanotechnology and immunotherapy.Frontiers in endocrinology · 2024Review
- Biological basis of bone strength: anatomy, physiology and measurement.Journal of musculoskeletal & neuronal interactions · 2020Review
- Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density.Journal of clinical & translational endocrinology · 2020Article
- The epigenetic impacts of endocrine disruptors on female reproduction across generations†.Biology of reproduction · 2019Review
- FSH Beyond Fertility.Frontiers in endocrinology · 2019Review
- Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment.F1000Research · 2019Review
- Bone Protective Effects of Danggui Buxue Tang Alone and in Combination With Tamoxifen or RaloxifeneFrontiers in pharmacology · 2018Article
- Hepatic magnetic resonance imaging with T2* mapping of ovariectomized rats: correlation between iron overload and postmenopausal osteoporosis.European radiology · 2014Article
- Role of Sost in Wnt signal pathway in osteoporosis rats and regulating effect of soybean isoflavones on Wnt signal pathway.Molecular biology reports · 2014Article
- Treatment effect ofExperimental and therapeutic medicine · 2014Article
- Pharmacological estrogen administration causes a FSH-independent osteo-anabolic effect requiring ER alpha in osteoblasts.PloS one · 2012Article
- Effects of polymorphisms in gonadotropin and gonadotropin receptor genes on reproductive function.Reviews in endocrine & metabolic disorders · 2011Review
- Postmenopausal hormone therapy: an Endocrine Society scientific statement.The Journal of clinical endocrinology and metabolism · 2010Review
- Bone phenotypes in response to gonadotropin misexpression: the role for gonadotropins in postmenopausal osteoporosis.International journal of general medicine · 2008Article
- Release of prostaglandin E(1) from N-(2-hydroxypropyl)methacrylamide copolymer conjugates by bone cells.Macromolecular bioscience · 2008Article
- Article
- ENA Actimineral Resource A restores bone loss and bone quality in ovariectomized rats.Molecular and cellular biochemistry · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although it has been known for some time that estrogen deficiency is a major pathogenetic factor for osteoporosis related fractures among postmenopausal women, the capability of estrogen (with or without a progestin) to prevent fractures has often been questioned. The publication of the data from the two hormone clinical trials of the Women's Health Initiative lays that discussion to rest. In both studies what have been considered a standard dose of conjugated estrogen with or without medroxyprogesterone acetate significantly reduced the risk of all fractures, including clinical vertebral fractures and hip fracture, in a population of postmenopausal women, average age 63 yr, not selected for osteoporosis by BMD. These results are particularly impressive given the difficulty of finding a fracture benefit in lower risk populations with other anti-resorptive agents. Surrogate data on lower doses of hormone therapy suggest a fracture benefit would be seen if studies were to be done. The other outcomes in WHI make it important to define appropriate clinical guidelines for use of hormone therapy for prevention of fractures in postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.